<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02716090</url>
  </required_header>
  <id_info>
    <org_study_id>ACH-DLP-03(01/13)</org_study_id>
    <nct_id>NCT02716090</nct_id>
  </id_info>
  <brief_title>Clinical Trial Phase III to Assess the Non-inferiority of Dalap Duo® Product Compared to Epiduo® in the Treatment of Acne Vulgaris</brief_title>
  <acronym>Narciso</acronym>
  <official_title>National Clinical Trial, Phase III, Monocentric, Randomized, Open, Controlled, Parallel Study to Assess the Non-inferiority of Dalap Duo® Product (0,1% Adapalene and 2,5% Benzoyl Peroxide Gel Cream) Compared to Epiduo® (0,1% Adapalene and 2,5% Benzoyl Peroxide Gel) in the Treatment of Acne Vulgaris in Population of Men and Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ache Laboratorios Farmaceuticos S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ache Laboratorios Farmaceuticos S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the non-inferiority of the product Dalap Duo® compared to Epiduo®
      medicine to treat acne. Half of the participants will receive Dalap Duo®, while the other
      half will receive Epiduo®.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigational product produced by Aché that will be evaluated in this trial is a cream
      gel, comprising 0.1% of adapalene 2.5% and benzoyl peroxide. It's a topical cream gel that is
      stored on a laminated tube containing 30 grams.

      Of the 376 research participants with acne vulgaris participating in the study, 188 will be
      treated with the investigational product Cream Gel.

      The duration of the participants in the study will be up to one hundred twenty-four days,
      contemplating screening visit, randomization visit, four follow-up visits, a final visit and
      a phone contact 30 days after final visit. Of the one hundred twenty and fourth days of the
      study period, the participants will be treated for eighty four days.

      Regarding the control group, the active comparator is Epiduo®, manufactured by Galderma
      Laboratories, and its formulation is composed of 0.1% adapalene 2.5% and benzoyl peroxide.
      This is a topical gel stored in laminated tube with 30 grams.

      Of the 376 research participants with acne vulgaris that will participate in the study, 188
      will be treated with the active comparator Epiduo®.

      The duration of the participants in the study will be up to one hundred twenty-four days,
      contemplating screening visit, randomization visit, four follow-up visits, a final visit and
      a phone contact 30 days after final visit. Of One hundred twenty and fourth days of the study
      period, the participants will be treated for eighty four days.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Due to budget limitations, the company decided to withdraw this study.
  </why_stopped>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of total acne lesion</measure>
    <time_frame>84 days</time_frame>
    <description>Percentage reduction of total acne lesion on the face other than the region of the nose by manual counting performed by the investigator.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction of number of inflammatory lesions</measure>
    <time_frame>07, 14, 28, 56 and 84 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in non-inflammatory lesions</measure>
    <time_frame>07, 14, 28, 56 and 84 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of acne through Global assessment of investigator</measure>
    <time_frame>07, 14, 28, 56 and 84 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficiency perceived by participant</measure>
    <time_frame>84 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Dalap Duo®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.1% of adapalene and 2.5% and benzoyl peroxide gel cream. Apply the product on the areas affected by acne once a day in the evening for 84 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epiduo®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.1% of adapalene and 2.5% and benzoyl peroxide gel. Apply the product on the areas affected by acne once a day in the evening for 84 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adapalene and Benzoyl peroxide Dalap Duo®</intervention_name>
    <arm_group_label>Dalap Duo®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adapalene and Benzoyl peroxide Epiduo®</intervention_name>
    <arm_group_label>Epiduo®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. female or male Participant

          2. Age older than or equal to 12 years;

          3. 30-100 non-inflammatory facial lesions, except in the nose region (comedo closed and
             open comedo - degree 1) and 20 to 50 inflammatory facial lesions, except in the nose
             region (papule and pustule - degree 2);

          4. Ability to understand and consent to participate in this clinical study, expressed by
             signing the consent form;

          5. Search Participant willing to not use, for the entire period of the study drugs,
             cosmetics and / or treatments for acne, according to the investigator, that may
             influence the study results, such as, but not limited to, treatment with oral and
             topical retinoids.

        Exclusion Criteria:

          1. Any finding of clinical observation (clinical assessment / physical) that is
             interpreted by the investigator as a risk to safety or which may interfere with the
             effectiveness of the treatment and research of the participants in the clinical trial;

          2. Any laboratory examination found that the investigator consider as safety risk or that
             may interfere with the effectiveness of the treatment and research of the participants
             in the clinical trial;

          3. Known hypersensitivity to the drug components used during the study;

          4. female participants with a history of polycystic ovary syndrome (Stein-Leventhal
             syndrome);

          5. Women with positive result for urinary beta human chorionic gonadotropin or gestation
             period or breastfeeding;

          6. Women in the reproductive age who do not agree to use acceptable contraception [oral
             contraceptives, injectable contraceptives, intrauterine device (IUD), hormonal
             implants, barrier methods, hormonal patch and tubal ligation]; other than surgically
             sterile (bilateral oophorectomy or hysterectomy) or sexual abstinence or who have not
             yet initiated sexual activity;

          7. Person who has participated in clinical trial protocols in the last twelve (12)
             months, unless the investigator considers that there may be direct benefit to him/her;

          8. Participant who has some kinship to the second degree or bond with employees or
             employees of Sponsor and Research Center;

          9. Women in menopausal or postmenopausal period;

         10. Any feature in the test areas (face) that according to the investigator may influence
             the results, for example, BUT NOT LIMITED TO moles, tattoos, scars, irritated skin,
             scratches, cuts and excess hair;

         11. Participants diagnosed with Diabetes Mellitus after evaluation of the result of the
             test, defined as the presence of the classic symptoms of diabetes mellitus assessed
             the visit V-1 associated with the higher level of casual plasma glucose or equal to
             200 mg / dL according to the American Diabetes Association (DIABETES CARE, VOLUME 33,
             SUPPLEMENT 1, JANUARY 2010);

         12. Presence of dermatoses related to diabetes mellitus (plantar ulcer, necrobiosis
             lipoid, annular granuloma, dermatophytosis, deep mycoses, bacterial infections,
             opportunistic infections);

         13. immune impairment;

         14. Dermatological diseases in the test area (face): vitiligo, psoriasis, atopic
             dermatitis;

         15. Participant using topical treatment for acne in the 15 days preceding the screening
             visit (V-1) or oral treatment for acne in the 30 days preceding the screening visit
             (V-1) or plan to use during the study period;

         16. Participant with cyst or lump in the face region;

         17. Use of medication and / or treatment contrary as described in item 11.2. of the
             Protocol;

         18. Other diseases or medications, according to the investigator, that would interfere
             directly in the results of the study or jeopardize the health of the participant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2015</study_first_submitted>
  <study_first_submitted_qc>March 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2016</study_first_posted>
  <last_update_submitted>February 14, 2017</last_update_submitted>
  <last_update_submitted_qc>February 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benzoyl Peroxide</mesh_term>
    <mesh_term>Adapalene</mesh_term>
    <mesh_term>Adapalene, Benzoyl Peroxide Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

